Aims: To investigate the value of immunohistochemical staining for the cell cycle protein proliferating cell nuclear antigen (PCNA) and flow cytometric S phase fraction in determining prognosis in endometrial stromal sarcoma, graded according to mitotic count. Methods: Seventeen endometrial stromal sarcomas from 13 patients treated at the Royal Marsden Hospital were analysed. Serial 5 um sections were cut for haematoxylin and eosin and immunohistochemical staining for PCNA, performed using the murine monoclonal antibody PC1O. PCNA positivity was expressed as a percentage of the total number of cells (PCNA index). Flow cytometric analysis was performed on nuclei extracted from paraffin wax sections. Results: In the five patients who died of disease within five years, PCNA index varied between <1% and 60% (mean 21%) and S phase fraction ranged from 11 3 and 20-1 (mean 13-8). Four patients who were apparently cured showed PCNA indices ranging from < 1% to 5% (mean 1.75%) and S phase fraction ranging from 1-4 to 3*5 (mean 2.3); and three patients alive with disease showed PCNA indices ranging from 1% to 15% (mean 8.6%) and S phase fraction ranging from 1X4 to 3 5 (mean 2.3). One patient who died from indolent local disease after nine years showed a PCNA of 1 or less and an S phase fraction of 0-9. Conclusions: PCNA staining was variable and therefore not a reliable prognostic indicator, but a high PCNA index was only found in those patients dying of disease within five years. A stronger association was seen between S phase fraction and prognosis; this also correlated well with histological grade determined by mitotic count. In individual borderline cases that are between low and high grade categories, these procedures may be useful.
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Endometrial stromal sarcomas are uncommon as are reports of case series.'-" Endometrial stromal sarcoma has traditionally been divided into histologically high and low grades on the basis of mitotic count (> 10/10 high power fields denoting high grade)2; implicit in the definition is a morphological similarity with the cells of normal endometrial stroma. Those sarcomas apparently arising in endometrium which do not display this feature are coming to be regarded as "poorly differentiated endometrial sarcomas" or just "endometrial sarcomas."3 Counting of mitotic figures is not always easily reproduced and may not be comparable between different cases,'2 rendering the reliability of the separation of tumours into low and high grades open to speculation. There is a reported correlation between grade and prognosis, supported by several authors; although low grade tumours are normally indolent and locally recurrent over a prolonged period, they may metastasise. It has also been suggested that mitotic count may not be the most useful criterion for predicting biological behaviour in these lesions, and that it is not necessarily directly related to S phase fraction.'
We have previously reported clinical data for a group of endometrial stromal sarcomas. " This study correlates these clinical data with results of three methods of assessing cell proliferation: mitotic count; S phase fraction determined by flow cytometry; and immunohistochemical reactivity with PC 10 (an antibody to proliferating cell nuclear antigen). ' I'CNA and S phase fraction ini enidonwrtrial stromial sancoma667 study). However, this success rate can be increased by controlling fixation more carefully (Gillett and Camplejohn, unpublished data). Our findings confirm those of August et al," who showed diploid complement in four cases of "endolymphatic stromal myosis" and one case of endometrial stromal sarcoma. They noted aneuploidy in four further cases referred to as "stromal sarcoma", which, according to their description, might be classified as nonstromal endometrial sarcomas. Indeed, one of the cases originally included in our study was excluded as a "non stromal" tumour; interestingly, this tumour also showed aneuploidy together with a noticeably raised S phase fraction (26&2) as well as the highest PCNA index (65%). These findings suggest that there is a definite biological difference between the sarcomas of endometrial stromal and those of "non-stromal" type. In the light of this the presence of aneuploidy in endometrial stromal sarcomas should be viewed as a worrying factor and should increase initiate careful histological review of this diagnosis.
The series is too small to know whether the additional information gained by ploidy studies and quantitative measurement of immunohistochemically located PCNA activity adds prognostic information over and above stage and grade. However, it seems likely that in individual cases, particularly those which histologically border between low and high grade, these procedures may be of value.
